Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiVis
- Development stage
- Preclinical
- Lead developer
- Holy Young BioMedical
- Administration
- Intravesical
01
Overview
VesiVis is a defined multi-molecular-weight hyaluronic acid (HA) formulation developed by Holy Young BioMedical (a spin-off of Holy Stone Healthcare) for the treatment of bladder disorders, specifically ketamine-induced cystitis (KIC). Administered via intravesical instillation, VesiVis replenishes the glycosaminoglycan (GAG) layer of the bladder, rebuilding urothelial barrier integrity and restoring voiding function. In preclinical models of KIC, VesiVis has been shown to promote urothelial barrier repair by restoring tight junction proteins (such as ZO-1 and E-cadherin) and uroplakin III (UPKIII) expression, while also attenuating inflammatory and nociceptive signaling pathways (including NGF, TNF-alpha, and P2X3).
- Brand names
- VesiVis
- Other names
- multi-molecular-weight HAmulti-molecular-weight hyaluronic acid
02
Targets
CD44 (CD44 antigen)HMMRICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on VesiVis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiVis.